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Abstract 
Epilepsy is a neurological disorder characterized by its debilitating epileptic seizures. There 
are generalized seizures, which affect the whole brain at once, and focal seizures, which start 
from one part of the brain. The most common focal epilepsy, is temporal lobe epilepsy 
representing almost 70% of all focal epilepsies. Around 30% of all patients are therapy 
refractory, therefore there is a huge demand to find new drugs and ways to help all patients 
with epilepsy. It has been previously found that synaptic proteins play a crucial role in 
epilepsy, and in previous studies the protein N-cadherin has been found to be decreased 4 
weeks after induced epilepsy in rats that did develop spontaneous seizures. In this study we 
set out to modulate n-cadherin protein expression with antibodies in order to evaluate if this 
could potentially be a novel method to reduce seizure frequency and seizure-induced 
cognitive deficits. For a more clinically realistic scenario some animals were given a 
combinatorial treatment of the antibody and an anti-epileptic drug named Keppra to see if any 
synergistic effect can be achieved. In the first pilot study we infused N-cadherin antibody for 
1 and 2 weeks to study the antibody distribution and suitable antibody concentration that 
would not induce overt morphological changes. In addition, we evaluated the behaviour of the 
rats. The preliminary results show that rats induced with 1000µg/ml antibody over the course 
of two weeks show no signs of bad health, although they had a tendency to be more anxious 
than the untreated rats. Future studies will reveal if N-cadherin antibody treatment has any 
effects on seizure frequency. 
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Introduction  
 
Epilepsy 
Epilepsy is a chronic disorder of the brain that is characterized by recurrent epileptic seizures 
and affects people all around the world. In the United States alone, it is estimated that 1 in 26 
people will develop epilepsy during their lifetime (Epilepsy, 2014) which makes it the fourth 
most common neurological problem with migraine, stroke, and Alzheimer’s disease occurring 
more frequently. As of 2015 there were about 39 million people with reported epilepsy (GBD 
2015 Disease and Injury Incidence and Prevalence Collaborators, 2016). The seizure severity 
can vary from small lapses of attention to severe and prolonged convulsions and muscle jerks 
and the frequency may vary as much as having several seizures per day to less than one seizure 
per year (WHO, 2016). The seizures can be categorized into two different groups, partial and 
generalized seizures. The partial seizures start in a specific part of the brain, often in the 
temporal lobe or specifically in the hippocampus (HPC). The symptoms of TLE includes 
confusion, altered mental status, chewing, drooling or automatism. Generalized seizures on the 
other hand start in both hemispheres at the same time and can be observed as loss of 
consciousness and often manifests as convulsive, tonic-clonic events. The generalized seizures 
require high metabolism and if the seizures are not stopped, life threatening symptoms such as 
cardiac or renal failure or electrolyte imbalance may be triggered (Tatum,2001). 
Epilepsy is diagnosed by electroencephalogram (EEG) which detects electrical activity on top 
of the brain scalp and magnetic resonance imaging (MRI), which uses strong magnetic fields, 
radio waves, and field gradients to form an image, to look at the structure of the brain. A person 
is diagnosed with epilepsy when they have had two unprovoked seizures, which are seizures 
that are not caused by a known and reversible medical condition such as alcohol withdrawal, 
low blood sugar, or sleep deprivation. Furthermore, patients who have remained seizure-free 
for the last 10 years with no medication for the past five years are considered to be resolved of 
their epilepsy (Fisher, 2014).  
The most common form of partial epilepsy is temporal lobe epilepsy (TLE) and it is commonly 
drug resistant. The affected area of the brain is often the hippocampus, which is an important 
component of the brain in humans and other vertebrates, playing a crucial role in forming long-
term memories from short-term memories and in spatial memory, which enables navigation. 
There are two hippocampi, one in each brain hemisphere, in humans and other mammals and 
belong to the limbic system which support a variety of functions including emotion, behavior, 
motivation and long term memory (Martin, 2003). The hippocampus is located under the 
cerebral cortex and contain two main parts, the hippocampus proper and the dentate gyrus. The 
hippocampus has the shape of a curved tube, resembling a seahorse or a ram’s horn (Cornu 
Ammonis) in which the abbreviation CA comes from when naming the hippocampal subfields; 
CA1, CA2, CA3, and CA4. The dentate gyrus consists of different cell types which are both 
excitatory and inhibitory, the primary excitatory cells receive information from outside of the 
hippocampus, including entorhinal cortex. The dendrites receive the information and transport 
it to the rest of the hippocampus via the axons of the granual cells. 
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Therapy 
There is available medication to manage the seizures and the drugs are most often 
anticonvulsant (NICE 2012) also called anti-epileptic drugs (AED), although the medication is 
only effective on 70% of all patients (Eadie, 2012). However, the efficacy of medication on 
patients with partial or focal epilepsy is only around 50% (Bergey, 2013). Most treatments 
involve modulating the activity of γ-aminobutyric acid (GABA) receptors or reducing the 
glutamatergic transmission, both of which are used inhibitory and excitatory synapses 
respectively. For those patients that are resistant to medication there is a last resort surgery 
which is the resection of the part of the brain which the seizures originate from (Duncan 2007). 
There are around 26 AEDs used in the treatment of seizures with different drugs treating 
different types of seizures (Epilepsy Society, 2014). For example, the drug Levetiracetam, 
which goes under the generic name of Keppra, is used in this study. The exact mechanism of 
levetiracetam is unknown, however, the drug binds to a synaptic vesicle glycoprotein SV2A 
(Lynch 2004) and inhibits presynaptic calcium channels (Vogl, 2012). Sometimes one drug is 
not enough to stop the seizures therefore combination of drugs is often utilized.  
Epileptogenesis 
The exact mechanism of epilepsy is unknown, however, excitatory neurons are believed to 
become more active and hyperexcitable (Goldberg, 2013). Epilepsy can be categorized into two 
groups, genetic/idiopathic and acquired. In idiopathic epilepsy the cause is not known but is 
usually associated with a genetic component and may include mutations of genes responsible 
for maintaining the excitatory/inhibitory (E/I) balance in the brain, eg ion channels as well as 
environmental factors can play a role. Acquired epilepsy on the other hand includes a 
precipitating injury or brain insult such as traumatic brain injury, including a brain infection, 
tumour, ischemic stroke or cortical dysplasia. These brain insults trigger a series of events that 
reorganize the brain network and make it more prone to developing spontaneous recurrent 
seizures. This process is termed epileptogenesis and can last from months to years. More 
specifically, aberrant molecular and cellular plasticity, neurogenesis, inflammation, 
neurodegeneration, neurochemical changes occur, which in combination or alone cause the 
inhibitory and excitatory circuits to reorganize which in turn lowers the seizure threshold 
(Pitkänen, 2002).  
One of the mechanisms thought to be important in epileptogenesis is the E/I balance in the 
brain. Synaptic proteins and scaffolding proteins that sit on the pre- and postsynaptic sites, 
presynaptic sites are the ones that send the message and postsynaptic sites are the ones that 
receive the message, on neurons are thought to play an important role in maintaining this 
balance (Chugh, 2015).  Previous studies have indicated altered expression in synaptic proteins 
in both patients and animal models of epilepsy. It has been recently found that synaptic proteins 
are altered in the brain at different time points following status epilepticus (SE). Interestingly, 
at 4weeks following SE, the excitatory adhesion molecule N-cadherin was decreased in animals 
that had developed epilepsy, whereas no change in expression was detected in animals that did 
not develop epilepsy following the insult (Avdic, 2017, manuscript). N-cadherin is found in 
neurons at both pre- and postsynaptic terminals. Each N-cadherin has a small part in the 
cytoplasm, that is anchored to the membrane and the rest of it is extracellular, which is the part 
that is used to adhere to other cadherins. The intracellular domain is connected to the 
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cytoskeleton by binding to beta-catenin molecules. N-cadherin is important due to its mediation 
of neuronal and growth cone migration when N-cadherin/beta-catenine links to actin in the early 
stages of development. In the later stages of synaptic development N-cadherin becomes more 
concentrated at excitatory synapses and it has been shown that a loss of N-cadherin at excitatory 
synapses has decreased the severity of kainic acid induced hippocampal seizures (Niikitczuk, 
2014). 
 
Models of acquired epilepsy 
Electrical models 
Kindling is an animal model used to mimic the symptoms of TLE and is widely used. The 
model applies repeated short electrical stimuli to hippocampus or amygdala over a long time 
period which results in a progressive increase in electrographic and behavioural seizure activity 
(Goddard, 1967). This model shares similarities with the human condition in terms of 
semiology and pharmacology used to help with the seizures (Loscher, 2002). 
In addition to kindling, a more acute model is used where electrical stimulation in hippocampus 
or amygdala develop SE that becomes selfsustained, no stimulation is needed for seizures to 
occur. Animals induced with SE get spontaneous recurring seizures and neuropathological 
changes including hippocampal sclerosis, severe neuronal cell loss also found in many patients 
with TLE. 
Chemical models 
Chemical compounds such as pilocarpine, which is a cholinergic agonist, and kainic acid,a 
glutamate analog, can induce SE (Loscher, 2002) and is administered either systematically or 
locally in the brain. Most animals develop spontaneous recurring seizures after a latent period 
of weeks to months.  
Traumatic brain injury models 
Some models want to mimic the human epileptic condition developed after a traumatic brain 
injury. These models include fluid-percussion, controlled cortical impact or ballistic injury 
models. All models use mechanical damaged to the brain and these animal models often have 
a long duration to the development of spontaneous seizures and the seizure frequency is 
substantially lower (Pitkänen, 2009).  
Aim 
The change in N-cadherin expression that we see at 4weeks post SE may reflect a compensatory 
mechanism in order to restore the E/I balance. Therefore, the aim of this project was to target 
N-cadherin with an antibody and modulate its expression in the brain in order to alter the 
epileptogenic state and hopefully affect the seizure frequency.  
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Materials and Methods 
 
Animals 
Adult male Sprague-Dawley rats weighing between 200-250 g were procured from Charles 
River (Germany). The animals were housed in 12 hrs light/dark cycle with ad libitum food and 
water. All experimental procedures followed the guidelines set by the Malmö-Lund Ethical 
Committee in Sweden for the use and care of laboratory animals. 
Group assignment 
Animals were divided into five groups shown in table 1 below. 
Table 1: Table showing planned animals group assignment followed by the number of animals 
Group Total number of animals 
N-Cad Concentration Determination 7 
Keppra 6 
SE Control 6 
Non-stimulated control (NSC) 9 
N-Cad + Keppra 6 
Total 34 
 
All animals had electrode, cannula and pump implanted. 
Surgeries, drug infusions and electrically-induced temporal status epilepticus 
Animals were anaesthetized with 2% isofluorane and implanted with a bipolar insulated 
stainless steel electrode (Plastics One, Roanoke, VA) into the right ventral CA1/CA3 region of 
the hippocampus (coordinates: 4.8 mm posterior and 5.2 mm lateral from bregma; and 6.3 mm 
ventral from dura, tooth bar set at -3.0 mm) for stimulation and recording. A unipolar electrode 
was placed between the skull and adjacent muscle to serve as ground electrode. Additionally, a 
brain infusion cannula (Brain infusion kit 1, Alzet) was implanted in the lateral ventricle 
(coordinates: 1.0 mm posterior and 1.5 mm lateral to bregma; and 3.5 mm ventral to the flat 
skull position with bregma as reference) in the ipsilateral hemisphere. Following a week of 
recovery after surgery, rats were subjected to electrically-induced temporal SE. Afterdischarge 
threshold was assessed by delivering a 1 s train of constant current balanced, biphasic, square-
wave pulses (1 ms duration, 50 Hz) at an initial current of 10 µA (base-to-peak), and increased 
by 10 µA increments at 1 min intervals until at least a 5s duration of afterdischarge was evoked. 
After 30 min, a 1 hour suprathreshold stimulation with 10 s trains of 1 ms, 50 Hz, biphasic, 
square-wave pulses was applied. Stimulation was interrupted every 9th min for 1 min of EEG 
recordings. Electrode-implanted non-stimulated rats served as controls (NSC). Only rats that 
displayed self-sustained EEG activity for 2 hours in the temporal lobe and mainly partial 
seizures e.g. orofacial twitches, nodding, drooling, and unilateral forelimb clonus, according to 
Racine´s scale, were included in this study (Racine 1972). Behavioural symptoms and EEG 
activity was completely interrupted after 2 hours of self-sustained SE by administration of 
pentobarbital (65 mg/kg, intraperitoneal injection).  
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Intracerebroventricular drug infusion 
After being anesthetized following SE, the osmotic pump was connected to the brain infusion 
cannula. Non-stimulated control rats were also connected with the pumps, only carrying 
vehicle. The osmotic pumps were placed in the subcutaneous pocket in the dorsal region of the 
neck. For the concentration determining part 1 week pumps (2001 1.0µl/hr, Alzet) were used 
and for the treatment 2 week pumps (2002 0.5µl/hr, Alzet). Table 2 shows the pumps and the 
concentrations used in the pilot study. 
Table 2: Table showing concentrations of treatment and following pump specs used for each treatment.  
Concentration 
[µg/ml] 
Model Reservoir 
Volume [µl] 
Pump Flow 
[µl/hr] 
10 2001 200 1.0 
80 2001 200 1.0 
200 2001 200 1.0 
300 2001 200 1.0 
500 2001 200 1.0 
1000 2002 200 0.5 
 
Western Blot 
In order to see if any N-cadhein was cleaved during the treatment and was present in the blood 
we performed western blot analysis on serum from animals treated with N-cadhein antibody. 
Cardiac blood was collected from animals before perfusion and incubated in room temperature 
for 1h. The saples were then centrifuged at 2000rpm for 30min, 4°C. The supernatant was 
collected, aliquoted and stored in -80°C until analysis.  
Protein samples were denatured at 99°C for 5 min in 2x Laemmli sample buffer (Biorad, Ger- 
many). Total protein of 10–20 μg (unless otherwise mentioned) was resolved on precast 4–15% 
mini-PROTEAN TGX (Biorad) sodium dodecyl sulphate polyacrylamide gels and transferred 
using Trans-Blot Turbo mini nitrocellulose transfer packs (Biorad). Following this, the 
membranes were blocked for 2 h at room temperature in tris-buffered saline (pH 7.4) with 0.2% 
(w/v) Tween 20 (TBS-T) containing 5% nonfat dried milk. Membranes were then incubated 
overnight at 4°C with primary antibodies diluted in TBS-T containing 0.5% bovine serum 
albumin (BSA) (Sigma). The only primary antibody used was Monoclonal Anti-N-Cadherin 
antibody produced in mouse purified from hybridoma cell culture (1:200 Sigma Aldrich, 
Germany). After washing, membranes were incubated with secondary antibody diluted in TBS-
T containing 0.5% BSA for 2 h at room temperature. Secondary antibody used was horseradish 
peroxidase-conjugated anti-mouse (1:1000 Sigma Aldrich). The membranes were then washed 
three times in TBS-T. Immunoreactive bands were subsequently visualized by enhanced 
chemiluminescence (Biorad), and images were acquired using Chemidoc XRS+ system 
(Biorad). 
Immunohistochemistry 
For analysis of adhesion molecules and inflammatory markers, rats were given an overdose of 
pentobarbital (250 mg/kg i.p.) and transcardially perfused with ice-cold 0,9% saline and ice-
cold PFA (4% in 0.1 M PBS, pH = 7.1-7.4). Brains were removed, post-fixed in 4% PFA 
overnight, and then dehydrated in 20% sucrose in 0.1 M PBS overnight, and then cut into 30 
µm-thick coronal sections using a microtome. The brains were marked in the right hemisphere 
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by a cut in cortex to determine which is left and right when examining. The brain was glued to 
a fixed holder using a cryomold (Tissue-Tek O.C.T Compound and Cryomolds) which hardens 
at -10°C, using dry ice, and fixates the brain for better sectioning.  
Free-floating sections were incubated with the appropriate primary antibody overnight at +4°C 
and secondary antibody for 2 h at room temperature. 
Following primary antibodies were used: mouse anti-N-cadherin (1:500 Sigma Aldrich, 
Germany), rabbit anti-IBA1 (1:500 Wako, Germany), and mouse anti-ED1 (1:200 Abd 
Serotech). Secondary antibodies used were: Alexa -488 donkey anti-mouse (1:200 Invitrogen, 
Sweden), biotynilated goat anti-rabbit (1:200 Vector Laboratories, UK), Alexa-488 conjugated 
streptavidin (1∶200, Jackson ImmunoResearch, UK), and Cy3-conjugated donkey anti-mouse 
(1:200 Jackson Immuno Research). Free-floating sections from perfused animals were mounted 
on gelatin-coated microscope slides and coverslipped with DABCO (Sigma) and Hoescht 
(Sigma) 1:1000. 
 
Statistical analysis 
Statistical analyses were performed with unpaired Student’s t-test when comparing two groups, 
using GraphPad Prism software and paired Student’s t-test when comparing within a group. 
Racine stages 
In order to quantify epileptic seizures, Ronald J. Racine suggested means to describe seizure 
intensities. As the intensity of the seizures increase, so does severity. All stages are a result of 
the action potentials causing the muscles to contract and relax, resulting in an involuntary and 
observable action (Racine, 1972).  
Stage 1, mouth and facial movements twitching 
Stage 2, head nodding  
Stage 3, forelimb clonus  
Stage 4, rearing with forelimb clonus 
Stage 5, rearing and falling with forelimb  
 
Behavioural tests 
In order to assess the cognitive function of memory, anxiety, and motor functions behaviour 
tests were conducted.   
Open Field 
Open field is used to measure locomotor activity and anxiety in individual rats. The field is 
quadratically formed with the dimensions 90cmx90cm divided into 16 squares 15cmx15cm and 
walls with the height of 40cm. The following parameters were measured each minute, time 
spent moving/not moving, grooming (yes or no), rearing (yes or no), time spent in the middle 
quadrant, and number of boxes crossed.  
Social Interaction 
Social interaction is used to measure the wellbeing and anxiety of rats. A rat with no surgical 
history was introduced to the rat being tested and the parameters measured each minute where, 
time spent interacting, total numbers of interactions, and if the testing rat is dominant or 
submissive.  
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Sugar Preference test  
Sugar preference test is used to measure anhedonia and depression. After a period of 6 hours 
without water two bottles were introduced to the rats, in which one has 2% glucose. The 
parameter looked at were the intake of the sugar water compared to total liquid intake.  
Y-maze 
Y-maze is used to measure the willingness of rodents to explore new environments and to assess 
memory. The maze is Y-shaped with three arms at 120° angle from each other. The rat was 
introduced into the middle of the maze and exploration of each arm is recorded. The definition 
of an entry into one arm was defined when all four limbs were within the arm. When the rats 
explored all three arms consecutively it was considered a spontaneous alternation performance 
(SAP) and when the rat revisited the previously visited arm it was considered an alternating 
arm return (AAR). 
Cylinder Test 
Cylinder test is used to measure motor and muscle functions and to evaluate a rats’ spontaneous 
forelimb use. The rat was put inside a glass cylinder for exploration. The parameters measured 
were the total usage of left and right forelimb each minute.  
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Results 
 
Concentration determination 
In order to determine a suitable antibody concentration for intracerebral treatment, a low and 
high dose were decided. The first concentrations tested were 10 and 80 µg/ml. After one week 
of antibody treatment immunohistochemistry on coronal slices using only secondary antibody, 
revealed no n-cad specific fluorescence binding to treatment antibody was found. As negative 
control, animals which also had pumps, although only containing KPBS, were stained with only 
secondary antibody. Figure 1 shows the lack of specific fluorescence staining around 
hippocampus and dentate gyrus with 80µg/ml treatment. All pumps were empty upon retrieval. 
 
Figure 1: Hippocampus stain with treatment of 80µg/ml, lacking in staining showing mostly background. 
Next, three different higher concentrations were tried, 200µg/ml, 300µg/ml, and 500µg/ml. 
Primary protein binding from the infused antibody were found after 300µg/ml and in 
500µg/ml administered near the injection site. Figure 2 shows fluorescence staining at 
hippocampus with 300µg/ml and near the ventricle with 500µg/ml treatment. 
 
Figure 2: Left picture shows staining of the dentate gyrus with 300µg/ml treatment and right picture shows staining around 
the cannula site with 500µg/ml treatment.  
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The concentration of 500µg/ml was deemed to be best suited for the treatment, due to its clearer 
staining. For the actual treatment, 2 week pumps are to be used instead of 1 week pumps. The 
infusion rate of the 2-week pump is half of the 1 week. In order to get the same amount of 
antibody in 2 the 2 weeks treatment, the concentration was  doubled. The working concentration 
for the 2 weeks treatment was therefore determined at 1000µg/ml. Figure 3 shows the 
fluorescence staining near the ventricle of 1000µg/ml on treated and control rat.  
 
Figure 3: Left picture shows staining around the ventricle with treatment of 1000µg/ml and right picture shows staining around 
the ventricle with no treatment. 
Western Blot 
Results from western blot showed no free n-cadherin in the blood.  
Determination of toxicity of working concentration 
To infuse 1000µg/ml antibody in the ventricle could cause damage and possibly lead to 
cognitive or behavioural deficiencies. To determine any alterations, several behaviour tests 
were conducted. The rats looked healthy, grooming them self and showing of shiny fur, and 
weighted within normal ranges, 300-350g.  
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Open Field 
The open field test showed a significant decrease in N-cadherin treated rats with less time 
moving in the middle of the box compared to controls (p < 0.05 for 10 minutes, p = 0.097 for 3 
minutes), which could indicate a higher level of anxiety. Although, the amount of time spent 
moving (p = 0.99 for 10 and 3 minutes) and the distance covered (p = 0.61 for 10 minutes, p = 
0.85 for 3 minutes) detected no significant difference, indicating intact locomotive functions. 
Figure 4 displays the average time, and number of boxes crossed in treated and control rats.  
 
Figure 4: A: Comparison graph of average time spent in the middle of the field with a significant difference for a total of 10 
minutes. B: Comparison graph of average time spent moving for a total of 10 minutes. C: Comparison graph of average 
number of boxes crossed for a total of 10 minutes. D: Comparison graph of average time spent in the middle of the field for a 
total of the first 3 minutes. E: Comparison graph of average time spent moving for a total of the first 3 minutes. F: 
Comparison graph of average number of boxes crossed for a total of the first 3 minutes. 
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Cylinder Test 
The cylinder test shows no significant difference in activity (p = 0.48 for 10 minutes, p = 0.39 
for 3 minutes) or predominant use of right or left paw (p = 0.32 for right paw comparison 10 
minutes, p = 0.68 for left paw comparison 10 minutes, p = 0.34 for right paw comparison 3 
minutes, p = 0.47 for left paw comparison 3 minutes between groups, p = 0.58 for left versus 
right 10 minutes within control group, p = 0.09 for left versus right 10 minutes within N-
cadherin treated group, p = 0.51 for left versus right 3 minutes within control group, p = 0.18 
for left versus right 3 minutes within N-cadherin treated group). Figure 5 shows graphs of left 
and right predominance between and within the groups. 
 
 
  
Figure 5: A: Comparison graph of average number of usage of paws for a total of 10 minutes. B: Comparison graph of 
average number of usage of the right paw for a total of 10 minutes. C: Comparison graph of average number of usage of the 
left paw for a total of 10 minutes. D: Comparison graph of average number of usage of paws for a total of 3 minutes  
E: Comparison graph of average number of usage of the right paw for a total of 3 minutes. F: Comparison graph of average 
number of usage of the left paw for a total of 3 minutes 
16 
 
Social Interaction Test 
The social interaction showed no significant difference in time spent interacting (p = 0.20 for 
10 minutes, p = 0.13 for 3 minutes) nor in the amount of interactions (p= 0.43 for 10 minutes, 
p = 0.75 for 3 minutes) between control and N-cadherin treated rats. Although a trend towards 
decreased time spent interacting could be observed in treated rats, however since the groups 
included few annimals (n=3/group) further investigation to determine this is needed. Figure 6 
compares time spent interacting and number of interactions between control and treated 
animals.  
 
Figure 6: A: Comparison graph of average time spent interacting for a total of 10 minutes. B: Comparison graph of average 
number of interactions for a total of 10 minutes. C: Comparison graph of average time spent interacting for a total of the first 
3 minutes. D: Comparison graph of average number of interactions for a total of the first 3 minutes 
Y-maze 
Y-maze showed no significant difference in spontaneous alternation performance (p = 0.53) 
and alternate arm return (p = 0.33). Figure 7 shows comparison graphs between groups. 
 
Figure 7: Left pictures shows comparison graph of spontaneous alternation performance and right picture shows comparison 
graph of alternate arm returns. 
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Sugar Preference Test 
The sugar preference test showed no significant difference in sugar preference (p = 0.57). 
Figure 8 shows comparison graphs between groups. 
C t r l N c a d
0
5
1 0
1 5
S
u
g
a
r
 P
r
e
f
e
r
e
n
c
e
 (
s
u
c
r
o
s
e
/w
a
t
e
r
)
C t r l
N c a d
 
Figure 8: Comparison graph showing sugar preference in rats as a ratio sugar water : water.  
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Inflammatory markers 
In addition to behaviour tests, immunofluorescence targeting one part glial population namely 
the microglia with IBA1 staining was done. Cells were counted to compare inflammation within 
hippocampus, from same side as the cannula was inserted (ipsilateral side). Cells were 
quantified in the granular cell layer (GCL), hilus, and in the molecular layer (ML) of the 
hippocampus. In Figure 9 and 10 the number of IBA1 positive cells in the hippocampus of 
control and treated rats are shown. No significant difference was found in the GCL (p = 0.14), 
hilus (p = 0.13), and in ML (p = 0.15).  
 
Figure 9: A: Cell count of Iba1 positive cells in the granular cell layer. B: Cell count of Iba1 positive cells in the hilus. C: 
Cell count of iba1 positive cells in the molecular layer. 
 
Figure 10: Iba1 fluorescence staining of the dentate gyrus of treated and control brain with arrows showcasing a typical cell 
counted.  
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Discussion 
The pilot study resulted in a concentration that was detectable. However, it is not yet known if 
the same concentration has any therapeutic effects. The administration of 1000µg/ml 
concentration showed no health damaging effects, although behaviour tests indicated some 
anxiety.  
Concentration Determination  
The used antibody in this study is a Monoclonal Anti-N-Cadherin antibody produced in mouse 
purified from hybridoma cell culture. The antibody is a IgG1 antibody originating from mouse 
with specificity for N-cadherin in chicken, monkey, rabbit, human, mouse and rat. It is deemed 
suitable for applications like flow cytometry, electron microscopy, immunocytochemistry and 
western blot. Reason for using this specific antibody is due to it having an extracellular epitope 
and the buffer it is contained in did not contain any preservatives. However, we are using it in 
vivo which it has not been tested for and the animal being used is rat. Due to the antibody 
originating from mouse an adaptive immune response might be triggered rendering the antibody 
ineffective. The antibody should bind to the extra cellular domain and block adhesion, or even 
cause phagocytic cells to remove it, as well as bind to the N-cadherin in the brain. The amount 
needed to get a detectable amount is high, while the therapeutic effect concentration might be 
much lower. This is however something we cannot evaluate until it is administered in epileptic 
animals. Another issue with the staining could be that the secondary antibody used has trouble 
finding and binding to the primary antibody, or that the secondary antibody is old and the 
fluorophores are losing efficacy. This is combated by using fresh secondary antibody and the 
fact that N-cadherin is extracellular should be enough to make it detectable. These are some 
drawbacks that cannot be evaded due to the uncharted territory of this study, using antibody as 
a treatment for epilepsy.  
Western Blot 
The Western blot detected no bands for n-cadherin in the blood. This finding indicates that the 
cleaved n-cadherin is not transported in the blood or is at unmeasurable amounts which is hard 
to trace. It could also indicate that the antibody can’t find its epitope due to the unfolding of the 
cleaved protein. No further evaluation of western blot was made due to this.   
Determination of toxicity of working concentration 
The behaviour tests conducted were all video recorded and analysed manually. To analyse 
videos by hand gives rise to a margin of error due to human factor, although most of the errors 
would be consistent throughout the tests. There is available technology which does the analyse 
which could reduce the error, however, this equipment is very expensive. Difference in day to 
day mood of the experimenter and sex could also play a role in the stress level of the rats 
although the effects could be negligible. Having multiple experimenters also gives rise to more 
deviations. Housing the rats alone in cages may affect the outcomes as rodents tend to become 
more depressed than if housed in a social environment, although all the rats in this study are 
caged alone which would affect all the rats in the same way.  
Open Field 
In the open field, rats were put in the middle of the box and recorded for 10 minutes. As time 
goes on and the rat familiarizes with the box, it stops to move around and starts feeling 
comfortable enough to start grooming. This gives a misrepresentation of the activity of the rat 
and is why all the measurements and comparisons are made in averages of 10 minutes and the 
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first 3 minutes in all tests.  
The treated rats in this study showed a significant difference (p < 0.05) in exploring the middle 
compared to control in the 10 minutes comparison, but showed only a trend (p = 0.097) in the 
first 3 minutes comparison. The activity was however unchanged in both groups, indicating 
increased anxiety in treated rats. To keep in mind is that the groups were small.  
Cylinder Test 
The rats were put inside a high glass cylinder and their movements were recorded for 10 
minutes. Each time one of the paws, left or right, was used against the glass it was counted. 
However, the cylinder was quite small in radius which gave the rats some trouble moving 
around and whichever side the glass was of the rat, that paw would be used one or more 
additional times than the opposite when trying to climb the glass wall. This was done on both 
sides which should minimise the error margin.  
The rats in this study showed no preference to neither left nor right paw, indicating no decrease 
in motor functions due to treatment. 
Social Interaction  
In this test, two rats were tested and recorded at the same time which resulted in the two cages 
being close to each other in order to both be captured on video. This sometimes made the testing 
rats curious of each other instead of the intruding rat. Two rats would on occasion start fighting 
loudly which would steal the attention of the neighbouring rats. The cages used were also small 
which forced the rats to interact more than when a bigger cage was used.  
Treated rats showed less interaction time compared to control, however not significant which 
would further indicate slight anxiety in treated rats.  
Y-maze 
The Y-maze is used to test out memory and spatial learning, which hippocampus governs. The 
maze was elevated in order to prohibit the rats from escaping and forcing them to explore the 
arms, however, the walls were not high enough to prohibit the rats from looking outside. The 
elevation might have served as additional drive for the rats to explore the arms. 
The rats showed no difference in spatial and memory learning indicating the treatment not 
damaging hippocampus.  
Sugar Preference 
The rats showed a clear preference to sugar water and no significant difference was found. 
This indicates that the rats show no signs of anhedonia.        
Inflammatory markers 
The cell count for Iba1 was incomplete as some of the rats did not have enough slices of the 
hippocampus mounted. This ended in some of the rats having only one or two counted series to 
make an average on. This will make the t-test less reliable, but what can be seen in the tests is 
that there is a tendency towards less inflammation in the hippocampal region of the treated rats. 
This could be due to the antibody used is a IGg1, which facilitates an immune response by 
attracting macrophages. Iba1 is a protein upregulated on activated microglia and macrophages. 
If the antibody facilitates the immune response, making the process faster, the activated 
microglia would recede faster and less would be found on stains.  
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Conclusion 
The larger aim of this project is to investigate whether a change in N-cadherin may alter the 
epileptogenesis and perhaps lower the seizure frequency. The first pilot study of the project was 
to assess the method by, in vivo use of an antibody. The first step was to find a working 
concentration which can be detected and measured without any adverse effects. In this regard, 
the result of having 1000µg/ml antibody might be in huge excess, this is however the only 
concentration at which we have been able to detect the infused antibody. If this concentration 
works or not, or is even too high, is to be further assessed. As of now, 1000µg/ml does not 
appear to have any dire outcome and will be used as treatment concentrations. Furthermore, a 
second pilot study is now ongoing to try and increase the spread of the antibody in the 
hippocampus by evaluating different cannula coordinates. The final step is the assessing of the 
synergistic effects with Keppra and N-cadherin antibody treatment will however not be 
performed by me due to lack of time. The project is ongoing and in the future assessments such 
as investigating what biological function the loss of N-cadherin at 4 weeks post SE has.  
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Hur påverkar klisterprotein epileptiska anfall? 
Hjärnan är ett fascinerande komplext organ som styr kroppen. För att hjärnan ska kunna 
skicka signaler använder hjärnan sig utav små budbärare. Dessa budbärare springer från en 
kontaktpunkt till en annan mellan nervceller och därmed vidarebefordrar meddelandet. 
Området där de springer mellan nervcellerna kallas för synaptiska klyftor, där vissa proteiner 
har som uppgift att klistra fast sig mot varandra från ena cellen till den andra för att inte 
klyftan ska bli för stor så att budbärarna går vilse. Ett av dessa klisterproteiner är N-cadherin. 
Vid sjukdomen epilepsi får man anfall som härstammar från att hjärnan börjar skicka signaler 
synkroniserat i hela eller en del av hjärnan. Dessa anfall kan uttrycka sig som allt från 
obehärskade muskelspasmer till små tidsperioder av mental frånvaro. Idag finns det medicin 
mot dessa anfall, där de flesta medicin påverkar budbärarna genom att till exempel göra så att 
budbärarna inte kan lika lätt skicka sitt budskap vidare och därmed göra det svårare för 
hjärnan att synkronisera signalerna. Denna medicin fungerar däremot inte på alla och en stor 
del av alla med epilepsi får ingen hjälp alls. 
Tidigare studier har visat att råttor som fått epilepsi men inte utvecklat återkommande 
spontana anfall har efter fyra veckors tid mindre av klisterproteiner N-cadherin i hjärnan. 
Detta tror man har hänt som en försvarsmekanism av hjärnan för att minska anfallen. Man tror 
att om det finns mindre av klisterproteinet som binder nervcellerna till varandra får man också 
en större synaptisk klyfta där budbärarna springer. Om detta område blir större blir även 
budbärarna mindre effektiva på att skicka sina meddelanden vidare och därmed motverkas 
synkroniseringen. 
För att studera detta fenomen har man använt så kallade antikroppar i råttor, en av kroppens 
egna försvarsmolekyler som fäster sig på specifika platser på proteiner och i denna studie har 
man använt en antikropp som fäster sig på N-cadherin. Antikroppar främjar kroppens egna 
försvar och kallar på så kallade makrofager som är kroppens egna underhållsarbetare som 
arbetar genom att äta upp allt som inte ska finnas där. Genom dessa antikroppar hoppas man 
på att kunna få bort en del av klisterproteinerna för att återskapa fenomenet man sett hos 
råttorna.  
Om detta ska kunna användas som framtida medicin måste man se en effekt hos råttorna och 
denna effekt ska innehålla så få biverkningar som möjligt, därför används en del beteende 
tester på råttorna. Hittills har försöken visat att råttorna som fått behandlingen mår generellt 
sätt bra men visar en liten trend på att vara ängsliga. Mer försök kommer att göras bland annat 
för att se hur behandlingen påverkar anfallen, även i kombination med ett redan tillgängligt 
läkemedel mot anfall. Förhoppningsvis kommer denna studie visa positiva resultat för att man 
därmed ska kunna forska vidare och skapa en helt ny sorts behandling mot epilepsi.  
 
